Randomised Phase I/II trial assessing the safety and efficacy of radiolabelled anti-carcinoembryonic antigen I(131 )KAb201 antibodies given intra-arterially or intravenously in patients with unresectable pancreatic adenocarcinoma

BACKGROUND: Advanced pancreatic cancer has a poor prognosis, and the current standard of care (gemcitabine based chemotherapy) provides a small survival advantage. However the drawback is the accompanying systemic toxicity, which targeted treatments may overcome. This study aimed to evaluate the saf...

Descripción completa

Detalles Bibliográficos
Autores principales: Sultana, Asma, Shore, Susannah, Raraty, Michael GT, Vinjamuri, Sobhan, Evans, Jonathan E, Smith, Catrin Tudur, Lane, Steven, Chauhan, Seema, Bosonnet, Lorraine, Garvey, Conall, Sutton, Robert, Neoptolemos, John P, Ghaneh, Paula
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2656541/
https://www.ncbi.nlm.nih.gov/pubmed/19243606
http://dx.doi.org/10.1186/1471-2407-9-66

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2656541/
https://www.ncbi.nlm.nih.gov/pubmed/19243606
http://dx.doi.org/10.1186/1471-2407-9-66

Ejemplares similares